PharmaLive: Xigen Closes Its Series A Financing Round with CHF 26m (21m USD)
A nice press release about a Swiss-based company working on intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. They have been at it for a while and this first round comes as a major achievement for the team that started at CHUV.